$JOE

Billionaire Bruce Berkowitz Reveals 76% Of Fairholme Capital Is in Just 1 Stock

Fairholme Capital's Q2 2026 filing shows 76% of its portfolio in St. Joe Company (JOE), with JOE reporting record Q2 revenue and net income growth. Fairholme also opened positions in Pfizer (PFE), Campbell Soup, and UPS, and added to Berkshire Hathaway (BRK-B) and Progressive (PGR).

Original reporting
Published Aug 19, 2026, 11:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 11:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Billionaire Bruce Berkowitz Reveals 76% Of Fairholme Capital Is in Just 1 Stock — source image
Decision brief

The 30-second read

$JOEBullishMed
01

Why it matters

The filing provides fresh insight into fund allocation, indicating strong conviction in JOE and modest diversification.

02

Market read

Fund concentration and new holdings may influence short‑term price action in the listed stocks.

03

What to watch

Potential regulatory or environmental risks to Florida land development.

Relevance 6/10Novelty 6/10Timing: post‑Q2 earnings release

Background

Fairholme Capital's Q2 2026 13F filing reveals its portfolio composition and new positions.

Company-level read

Ticker impact

$JOEBullishHigh confidence
Context

13F filing shows Fairholme holds 76% of its portfolio in JOE and reports record Q2 revenue.

Expected impact

potential upside as fund adds to buying pressure

Evidence & confidence

Fairholme's sizable stake and Q2 beat suggest strong near‑term support.

$PFEBullishMedium confidence
Context

Fairholme opened a new position of 231,000 Pfizer shares valued at $5.56 M.

Expected impact

small upward pressure

Evidence & confidence

Entry size is modest relative to market float.

$UPSNeutralLow confidence
Context

Fairholme added 23,800 UPS shares valued at $2.56 M.

Expected impact

minimal effect

Evidence & confidence

Position size is small compared with daily volume.

$PGRBullishMedium confidence
Context

Fairholme increased its holding in Progressive (PGR).

Expected impact

slight upside

Evidence & confidence

Adds to existing exposure, but no size disclosed.

$BRK-BNeutralLow confidence
Context

Fairholme added to its Berkshire Hathaway (BRK-B) position.

Expected impact

no material impact

Evidence & confidence

BRK-B is highly liquid; small addition is immaterial.

Market effects

Highlights value‑oriented fund activity in real‑estate and consumer staples.

Northwest Florida land development exposure may attract regional investors.

Limited to US equity markets and fund‑flow dynamics.

Counterpoint

Concentration risk could backfire if JOE faces a downturn.

Key entities

  • Fairholme Capital

    Value‑focused investment firm led by Bruce Berkowitz.

  • St. Joe Company

    Northwest Florida land developer reporting record Q2 results.

Related articles

$UPSHighAI 8/10

70% of UPS Packages Will Be Handled by Machines This Holiday Season

UPS expects 70% of holiday packages to be handled by automated sorting, according to CEO Carol Tomé. The company's shares rose 5.75% on Oct. 27, 2026, following the announcement. UPS is transitioning to a sensing network using RFID tags, aiming for 6 million labeled packages daily in 2027. The company anticipates a 25% rise in daily volume from Q3 to Q4, with a 1.3% year-over-year decrease due to reduced volume from Amazon.

$UPSHighAI 9/10

Key facts: NYSE:UPS Q3 Beat; Raises 2026 Guidance, Shifts to Logistics

UPS reported Q3 revenue of $22.9B (+7% YoY) and adj. EPS of $1.69. The company raised 2026 guidance, targeting revenue of ~$92.6B, adj. op profit of $8.75B, adj. EPS of $7.28, and FCF of ~$6.1B. UPS is shifting focus to higher-margin logistics services, including healthcare, aiming for >$13B in healthcare revenue by 2026. Analysts increased price targets following the Q3 beat.

$PFEHigh

Talzenna and Xtandi Win FDA Approval for Earlier HRR-Mutated Metastatic Prostate Cancer, With Anemia the Key Trade-Off

The FDA approved Pfizer's Talzenna (talazoparib) with Xtandi (enzalutamide) for earlier-stage metastatic prostate cancer with HRR mutations. The approval is based on the TALAPRO-3 trial, showing a 52% reduction in cancer progression risk. About 25% of patients may qualify, but serious anemia is a common side effect. Pfizer estimates the market impact, and further survival data are pending.

$UPSMedAI 8/10

UPS Cuts Its Workforce and Closes Buildings While Revenue Rises 6.7% to $22.9 Billion in Third Quarter

UPS reported Q3 2026 revenue of $22.9B, up 6.7%, while reducing its operational workforce and closing some buildings. The company expects $3B in cost savings for the year, with $1.4B-$1.6B in restructuring costs. U.S. domestic revenue rose 4.5% to $14.9B, and international revenue increased 7.1% to $5.0B. GAAP EPS was $1.37, and non-GAAP adjusted EPS was $1.69. Full-year guidance was raised to $92.6B in revenue and $8.75B in non-GAAP adjusted operating profit.

$JOEMed

THE ST. JOE COMPANY REPORTS THIRD QUARTER AND FIRST NINE MONTHS OF 2026 RESULTS AND INCREASES QUARTERLY DIVIDEND BY 13% TO $0.18 PER SHARE

ST JOE Co (JOE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ THE ST. JOE COMPANY REPORTS THIRD QUARTER AND FIRST NINE MONTHS OF 2026 RESULTS AND INCREASES QUARTERLY DIVIDEND BY 13% TO $0.18 PER SHARE ​ Highlights for the third quarter of 2026 as compared to the third quarter of 2025. The comparability of period over period